KIAA0317 regulates pulmonary inflammation through SOCS2 degradation

Area of Science:

• Immunology
• Molecular Biology
• Pulmonary Medicine

Background:

• Proinflammatory cytokine release is key in acute lung illnesses like pneumonia and ARDS.
• Suppressors of cytokine signaling (SOCS) proteins, especially SOCS2, are anti-inflammatory mediators.
• Mechanisms regulating SOCS2 protein levels were previously undescribed.

Purpose of the Study:

• To elucidate the regulatory mechanism of SOCS2 protein.
• To investigate the role of ubiquitin E3 ligase KIAA0317 in SOCS2 regulation and pulmonary inflammation.
• To evaluate a small molecule inhibitor of KIAA0317 as a potential therapeutic strategy.

Main Methods:

• Investigated KIAA0317's role in SOCS2 degradation in vitro.
• Utilized KIAA0317-knockout mice to assess in vivo pulmonary inflammation.
• Administered a KIAA0317 inhibitor (BC-1365) in mouse models of lung inflammation.

Main Results:

• KIAA0317 mediates SOCS2 degradation, exacerbating inflammation in vitro.
• KIAA0317 depletion ameliorated pulmonary inflammation in vivo.
• KIAA0317-knockout mice showed resistance to LPS-induced lung inflammation.
• The small molecule inhibitor BC-1365 prevented SOCS2 degradation and reduced lung inflammation.

Conclusions:

• KIAA0317 is a critical regulator of pulmonary inflammation via SOCS2 degradation.
• KIAA0317 represents a potential therapeutic target for acute lung inflammatory diseases.
• Targeting KIAA0317 may offer a novel strategy for treating conditions like pneumonia and ARDS.